Tango Therapeutics Inc

Tango Therapeutics operates with a capital structure that is entirely equity-funded, as it has no long-term debt and a debt-to-equity ratio of 0.0. The company maintains a strong liquidity position, with $112.28 million in cash and equivalents and a current ratio of 16.32, indicating a robust ability to meet short-term obligations. However, the company has negative operating and free cash flows of -$138.89 million and -$100.34 million, respectively, reflecting ongoing operational losses. Profitability metrics are negative, with a return on equity of -29.35% and a return on assets of -25.48%, both significantly below the industry median for biotechnology firms. These figures suggest that the company is not currently generating returns for shareholders or effectively utilizing its assets to generate profit. The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic diversification provided in the available data. This lack of segment or geographic diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another. Looking ahead, Tango Therapeutics is expected to continue experiencing revenue growth, though the exact magnitude is not quantified in the available data. The company's capital expenditures are relatively modest at -$1.05 million, indicating a focus on maintaining operations rather than expanding infrastructure. The company's research and development outlook is positive, driven by the advancement of its TANGO platform and pipeline candidates. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's ongoing net losses and negative cash flows suggest a potential need for future financing, which could lead to share dilution. No dilution sources were identified in the available documents, and the near-term probability of dilution is assessed as low. Recent filings and transcripts indicate that Tango Therapeutics is actively advancing its clinical pipeline, with several programs in early-stage development. The company has not disclosed any material events or regulatory actions that would impact its operations in the near term.